5. (Amended) The method of claim 1 wherein the anti-ErbB2 antibody induces cell death.

A2

6. (Amended) The method of claim 1 wherein the anti-ErbB2 antibody induces apoptosis.

A3

8. (Amended) The method of claim 1 wherein the tumor is cancer.

A4

20. (Amended) The method of claim 1 wherein the antibody is an antibody fragment.

22. (Amended) The method of claim 1 wherein the maytansinoid is maytansine.

A5

23. (Amended) The method of claim 1 wherein the maytansinoid is maytansinol.

24. (Amended) The method of claim 1 wherein the maytansinoid is a maytansinol ester.

A6

27. (Amended) The method of claim 1 wherein the antibody and maytansinoid are conjugated by a bispecific chemical linker.

A7

29. (Amended) The method of claim 1 wherein the antibody and maytansinoid are conjugated by a linking group selected from the group consisting of a disulfide, thioether, acid labile, photolabile, peptidase labile, and esterase labile group.

A8

34. (Amended) The method of claim 1 further comprising the administration of a second antibody which binds ErbB2.

A9

42. (Amended) The method of claim 1 wherein the conjugate is administered weekly at a dose of 0.1 to 5 mg/kg body weight for 4 to 6 weeks, followed by maintenance treatment with unconjugated anti-ErbB2 antibody.

46. (Amended) The method of claim 1 wherein said treatment has an improved objective response rate compared to treatment with huMAb4D5-8 (HERCEPTIN®) alone.

A10 sub B5

47. (Amended) The method of claim 1 wherein said treatment has a longer duration of response than treatment with huMAb4D5-8 (HERCEPTIN®) alone.